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ABSTRACT
Carbapenemase-producing Enterobacteriaceae (CPE) is an important and increasing threat 
to global health. From July to September 2017, 20 inpatients at a tertiary care hospital in 
Korea were either colonized or infected with carbapenem-resistant Escherichia coli strains. All 
of E. coli isolates co-produced blaNDM-5 and blaOXA-181 carbapenemase genes and shared ≥88% 
clonal relatedness on the basis of a cladistic calculation of the distribution of pulsed-field 
gel electrophoresis patterns. Rapid detection of CPE is one of the most important factors to 
prevent CPE dissemination because it takes long time for CPE to become negative.
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Carbapenemase-producing Enterobacteriaceae (CPE) is an important and increasing threat to 
global health. The most clinically significant carbapenemase genes include the following 
types: blaKPC, blaIMP, blaVIM, blaNDM, and blaOXA, mostly identified from Klebsiella pneumoniae 
as the source of nosocomial outbreaks [1]. Specifically, blaNDM and blaOXA co-producing 
Enterobacteriaceae are emerging as a serious challenge for treatment, infection control, and 
public health [1-3]. Globally, the co-existence of blaNDM-5 and blaOXA-181 genes was first detected 
in K. pneumoniae, followed by Escherichia coli [2]. Similarly, in Korea, a blaNDM-5 and blaOXA-181 
coproducing K. pneumoniae strain was first detected in 2014 [4], and by 2017, our hospital 
witnessed the first case caused by blaNDM-5 and blaOXA-48 co-producing uropathogenic E. coli [5].
The period of surveillance continued from July to September of 2017. Twenty patients 
harbored CPE; we numbered the patients in order from P1 to P20. The E. coli strain carried 
by P5 and P6 was isolated from blood, while that carried by P1, P2, and P19 was isolated 
from urine. Other E. coli strains implicated in the outbreak were isolated as part of the stool 
surveillance procedure undertaken to detect the presence of CPE. During the surveillance 
period, CPE outbreak control action comprises of three steps which are coordinated by 
Infect Chemother. 2019 Jun;51(2):177-182
https://doi.org/10.3947/ic.2019.51.2.177
pISSN 2093-2340·eISSN 2092-6448
Brief Communication
Kwangjin Ahn  1, Gyu Yel Hwang1, Young Keun Kim2,3, Hyo Youl Kim  2,3,  
Hye Ran Jeong3, Jun Sung Hong4, and Young Uh  1,3
1 Department of Laboratory Medicine, Yonsei University Wonju College of Medicine, Wonju Severance 
Christian Hospital, Wonju, Korea
2 Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju Severance Christian 
Hospital, Wonju, Korea
3 Infection Control Department, Yonsei University Wonju College of Medicine, Wonju Severance Christian 
Hospital, Wonju, Korea
4 Department of Laboratory Medicine and Research Institute of Antimicrobial Resistance, Yonsei University 
College of Medicine, Seoul, Korea
Nosocomial Outbreak Caused by 
NDM-5 and OXA-181 Carbapenemase 
Co-producing Escherichia coli 
Received: Sep 20, 2018
Accepted: Feb 13, 2019
Corresponding Author: 
Young Uh, MD, PhD
Department of Laboratory Medicine, Yonsei 
University Wonju College of Medicine,  
20 Ilsan-ro, Wonju 26426, Korea. 
Tel: +82-33-741-1592
Fax: +82-33-731-0506
E-mail: u931018@yonsei.ac.kr
Hyo Youl Kim, MD, PhD
Department of Internal Medicine, Yonsei 
University Wonju College of Medicine, 
20 Ilsan-ro, Wonju 26426, Korea.
Tel: +82-33-741-0518
Fax: +82-33-741-1206
E-mail: hyksos@yonsei.ac.kr
Copyright © 2019 by The Korean Society of 
Infectious Diseases and Korean Society for 
Antimicrobial Therapy
This is an Open Access article distributed 
under the terms of the Creative Commons 
Attribution Non-Commercial License (https://
creativecommons.org/licenses/by-nc/4.0/) 
which permits unrestricted non-commercial 
use, distribution, and reproduction in any 
medium, provided the original work is properly 
cited.
ORCID iDs
Kwangjin Ahn 
https://orcid.org/0000-0002-3558-6203
Hyo Youl Kim 
https://orcid.org/0000-0001-7827-902X
Young Uh 
https://orcid.org/0000-0002-2879-7870
Conflict of Interest
No conflicts of interest.
Author Contributions
Conceptualization: HYK, YU. Data curation: 
HYK, YU. Formal analysis: YU. Investigation: 
JSH, KA. Methodology: YU. Project 
administration: YU. Resources: GYH, YKK, HRJ. 
Software: KA, YU. Supervision: YU. Validation: 
KA, YU. Visualization: KA, YU. Writing - original 
draft: KA. Writing - review & editing: KA, YU.
infectious disease specialists. The steps as follows: First, immediately transfer the patient 
to a single-patient room when carbapenem-resistant Enterobacteriaceae (CRE) is detected at 
the site of infection. The ward 111 (111W), consisting of single-patient rooms, was used as 
the isolation ward. Second, collect stool specimens from patients who were hospitalized in 
the same room as the index patient. If CRE is detected in the stool surveillance study, the 
new patient harboring the CRE is also immediately transferred to the cohorting room or 
another single-patient room. This step is essential for screening CRE carrier. Third, decide 
about discontinuing patient isolation-and-contact-related precautions. Discontinuation of 
patient isolation depends on whether CRE is isolated in three consecutive rounds of testing, 
undertaken every 3–7 days with the same specimen type. If it is difficult to obtain the same 
type of specimen, for example, the cerebrospinal fluid, pleural fluid, or peritoneal fluid, only 
stool specimen is tested. If the cohort patient meets the criteria for isolation, the patient is 
moved to another ward for proper medical treatment. Else, if the condition of the patient is 
good, he/she is discharged, after detailed educating about self-hygiene. For the investigation 
of clinical and laboratory characteristics of CPE outbreak strains, data were extracted from 
the electronic medical records, followed by decoding. The study was exempted from the 
Institutional Review Board (IRB) of Yonsei Wonju Severance Christian Hospital according 
to the government regulation. Based on this exemption, the study also received a waiver of 
consent from the same IRB (approval no. CR318306).
Blood samples drawn for determining the bacteremia were handled in the same way, 
previously [5]. Urine specimen was inoculated onto 5% sheep blood agar plate (KOMED 
Life Science Co., Seongnam, Korea) and MacConkey agar plate (BD Diagnostic Systems, 
Sparks, MD, USA), and then incubated overnight at 35°C. All stool swab specimens for 
CPE screening were inoculated in the selective chromogenic medium (CHROMagar KPC, 
Hangang, Gunpo, Korea). The CRE isolates obtained from the clinical specimen were tested 
by the Modified Hodge test, carbapenemase inhibition test, and CarbaNP test (bioMérieux, 
Durham, NC, USA) [6], and then, the CPE suspects were tested by XpertCarba-R assay 
(Cepheid, Sunnyvale, CA, USA) [5]. Each time a CPE was isolated, the subcultured colony 
was delivered to the Korea Centers for Disease and Prevention (KCDC) for the confirmation 
of the carbapenemase genotype, and KCDC gave feedback about the type of carbapenemase 
genes present. The entire bacterial genome of 20 E. coli isolates was subjected to DNA 
fingerprinting by pulsed-field gel electrophoresis (PFGE) [7].
The total number of patients in the outbreak group was 20 (10 males, 10 females; age, 52–93 
years; mean age, 71 years). The hospital admission period of outbreak patients was from 
8th May to 29th Nov., 2017. The inpatient days ranged from 8 to 128 days (mean, 43 days). 
None of the outbreak patients expired during the hospitalization period. During the one 
year of follow-up, 16 patients were able to follow-up. Of 16 follow-up patients, 10 patients 
were proven culture-negative for CRE. Of them, CPE conversion time from CPE positive 
to CPE negative was 12 to 205 days, with an average of 76 days (Table 1). Because stool CPE 
screening was performed for all patients who were admitted to same ward as CPE patients, 
the incidence of number of CPE patients per 1,000 admissions was increased to 9.96. At 
the same time, eight CPE patients were discharged in 2 weeks (Fig. 1). The most common 
underlying diseases were cancer (n = 7) and cardiac disease (n = 4). All outbreak E. coli isolates 
were resistant to all antimicrobial agents tested (ampicillin, ampicillin/sulbactam, timentin, 
piperacillin, piperacillin/tazobactam, cefepime, cefotaxime, ceftazidime, aztreonam, cefoxin, 
imipenem, meropenem, doripenem, gentamicin, tobramycin, ciprofloxacin, levofloxacin, 
and trimethoprim/sulfamethoxazole), except amikacin.
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XpertCarba-R assay (Cepheid) showed that all outbreak E. coli isolates carried blaNDM and blaOXA 
genes. KCDC confirmed that the exact CPE genes were blaNDM-5 and blaOXA-181. The 20 E. coli 
isolates showed highly clonal similarity (>88%) on the basis of PFGE patterns. Therefore, the 
outbreak of blaNDM-5 and blaOXA-181 coproducing E. coli is likely to be concluded as clonal spread 
in this study (Fig.2).
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Table 1. Clinico-epidemiological findings of the patients involved in the outbreak
Patient 
No.
Specimen Age, 
years
Sex Underlying  
diseases
Admission  
date
Ward  
movement
Reported date  
as CPE positive
Discharge  
date
Time to CPE 
conversion, days
P1 Urine 76 F Coronary artery disease 8-May-2017 51W 14-Jul-2017 14-Jul-2017 107
P2 Urine 69 F Pseudomembraous colitis 13-Jul-2017 111W ← 92W 29-Jul-2017 14-Aug-2017 12
P3 Stool 78 F Avascular necrosis of hip 17-Jul-2017 92Wa 4-Aug-2017 4-Aug-2017 51
P4 Stool 79 F Common bile duct stone 11-Jul-2017 92Wa 4-Aug-2017 4-Aug-2017 (287)b
P5 Blood 77 M Esophageal cancer 7-Aug-2017 EICU 4-Sept-2017 30-Sept-2017 No follow-up
P6 Blood 93 F Septic shock 9-Aug-2017 EICU 4-Sept-2017 1-Sept-2017 No follow-up
P7 Stool 68 F Heart failure 18-Jun-2017 EICUc 8-Sept-2017 2-Oct-2017 No follow-up
P8 Stool 46 M Cerebral infarction 7-Aug-2017 EICUc 8-Sept-2017 9-Nov-2017 17
P9 Stool 77 F Acute respiratory failure 18-Aug-2017 EICUc 8-Sept-2017 8-Nov-2017 20
P10 Stool 81 M Septic arthritis 22-Aug-2017 EICUc 8-Sept-2017 29-Nov-2017 (81)b
P11 Stool 77 F Heart failure 23-Aug-2017 EICUc 8-Sept-2017 11-Sept-2017 211
P12 Stool 60 M Empyema, pressure sore 23-Aug-2017 102W ← EICUc 8-Sept-2017 8-Sept-2017 No follow-up
P13 Stool 76 M Heart failure 1-Sept-2017 73W ← EICUc 8-Sept-2017 9-Sept-2017 85
P14 Stool 70 M Esophageal cancer 27-Aug-2017 111W ← 102Wd 13-Sept-2017 17-Sept-2017 (53)b
P15 Stool 63 M Submandibular gland cancer 16-Jul-2017 111W ← 102Wd 13-Sept-2017 21-Nov-2017 130
P16 Stool 75 M Urinary tract infection 18-Aug-2017 102Wd 13-Sept-2017 13-Sept-2017 (131)b
P17 Stool 80 M Ascending colon cancer 30-Aug-2017 102Wd 13-Sept-2017 13-Sept-2017 (37)b
P18 Stool 63 M Rectal cancer 8-Sept-2017 111W ← 102Wd 13-Sept-2017 20-Sept-2017 (48)b
P19 Urine 65 F Cervix cancer 8-Sept-2017 22W 19-Sept-2017 19-Sept-2017 205
P20 Stool 52 F Cervix cancer 11-Sept-2017 111W ← 22We 20-Sept-2017 29-Sept-2017 40
aPatients who were hospitalized in the same room (92W) as the patient No. P2.
bNumber in parentheses means stool sample continued to yield CPE during the follow-up.
cPatients who were hospitalized in the same room (EICU) as the patient No. P5 and P6.
dPatients who were hospitalized in the same room (102W) as the patient No. P12.
ePatient who was hospitalized in the same room (22W) as the patient No. P19.
CPE, carbapenemase producing Enterobacteriaceae; F, female; W, ward; M, male; EICU, emergency intensive care unit.
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Figure 1. Epidemic curve caused by NDM-5 and OXA-181 coproducing Escherichia coli between July to November 2017.
The occurrence of carbapenem resistance has gained immense notoriety as an important 
public health threat because carbapenems have been used as the last option for the treatment 
of infections caused by multidrug-resistant gram-negative bacteria. Therefore, CDC has 
placed great emphasis on hand hygiene and rapid correspondence of CPE transmission 
[8, 9]. Interventions to control CPE are evolving as more data and experience become 
available [10]. CDC recommendations to prevent CRE transmission in healthcare settings 
are as follows: hand hygiene, contact-related precautions, healthcare personnel education, 
minimum and appropriate use of devices, timely laboratory notification, inter-facility 
communication/identification of CRE patients at admission, antimicrobial stewardship, 
environmental cleaning, patient and staff cohorting, contact screening of CRE patients, and 
active surveillance testing. When the source of CPE outbreak is clear, outbreak management 
is easier [11, 12]. However, it is rather difficult to determine the cause of a CPE outbreak; it 
could be a point or continuing source or nosocomial cross-transmission [4].
On discharge of CRE patients, terminal cleaning of the CRE patient rooms should be 
performed. In these situations, because of the time required to obtain the microbiological 
results for the initial CRE patient and to organize the survey, most or all patients who 
stayed in the ward at the same time as the index CRE patient have often been discharged. In 
such situations, it is necessary to screen contacts at maximum risk for transmission (e.g., 
roommates), even if they have been discharged or moved to another ward. Therefore, the 
basic concept for the prevention of CPE transmission is early detection of CPE, and CPE 
patients are recommended to return home when they are in a position to perform their 
daily tasks. To ensure rapid and sensitive detection of CPE, our laboratory moved from the 
modified Hodge test and cabapenemase inhibition test to Carba NP test. Stool CPE screening 
was performed for all patients who were admitted to same ward as CPE patients. All CRE 
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Figure 2. Pulsed-field gel electrophoresis profiles of XbaI-digested total DNA of 20 NDM-5 and OXA-181 
coproducing Escherichia coli isolates, compared to E. coli ATCC 25922.
with positive Carba NP test were confirmed by KCDC. The CRE or CPE colonized patients 
were then evaluated for early discharge by the infection control physician.
While some patients missed follow up in this study, conversion to CPE negativity also 
needed 12–205 days. Lai, et al. reported that persistent vancomycin-resistant Enterococcus 
carriers needed 39–421 days to become free of colonization [13]. Karki, et al. suggested that 
in the absence of recent risk factors such as hospitalization or antibiotic use, patients with a 
remote history of vancomycin-resistant Enterococcus colonization (>4 years) might no longer 
require isolation-and-contact-related precautions [14]. Although KCDC defined that three 
consecutive negative cultures for CRE is required to possibly confirm a patient as free of 
colonization, a criterion that accurately defines a status free of colonization has not yet been 
established by evidence-based studies.
Although our outbreak E. coli strain carried two different carbapenemase producing genes, 
namely, blaNDM-5 and blaOXA-181, all CPE patients who could be followed up, survived. There 
is no single best approach; instead, the decision should be guided by local epidemiology, 
resource availability, and the likely clinical impact of a CRE outbreak. In particular, in acute 
settings like ours, if the infection control team fails to ensure early control of CPE outbreak 
transmission, patients who can opt for homecare are advised an early discharge. For the 
proper functioning of these systems, it is imperative that the home-visit system infrastructure 
by the healthcare provider is built according to the national policy.
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